Press Releases

May 27, 2010
XANODYNE ANNOUNCES PLANNED PRESIDENT & CEO SUCCESSION

May 7, 2010
XANODYNE ANNOUNCES RENEWED FOCUS ON PAIN MANAGEMENT MARKET

April 1, 2010
XANODYNE AND FERRING ANNOUNCE CO-PROMOTE FOR ZIPSOR

March 10, 2010
Xanodyne named to Top 50 List by Wall Street Journal

November 16, 2009
XANODYNE ANNOUNCES FDA APPROVAL OF LYSTEDA™ (tranexamic acid) FOR TREATMENT OF WOMEN WITH HEAVY MENSTRUAL BLEEDING

November 12, 2009
XANODYNE EXPANDS U.S. SALES FORCE AND LAUNCHES ZIPSOR™ (DICLOFENAC POTASSIUM) LIQUID FILLED CAPSULES

October 29, 2009
XANODYNE RAISES $50 MILLION IN EQUITY FINANCING

July 13, 2009
Xanodyne Announces New Executive Team Members

July 7, 2009
U.S. Food and Drug Administration and Xanodyne Agree on a Plan to Keep Propoxyphene-Containing Products available as Treatment Options for the Management of Mild to Moderate Pain

June 17, 2009
Xanodyne Receives Approval From the U.S. Food and Drug Administration for ZIPSOR™ (diclofenac potassium) Liquid Filled Capsules

June 4, 2009
Xanodyne Announces New President/CEO and Completes $38 million equity financing

April 2, 2009
Xanodyne’s New Drug Application for the Treatment of Heavy Menstrual Bleeding (Menorrhagia) Accepted for Filing with a Priority Review Classification

January 30, 2009
The Darvon and Darvocet product lines were the subject of an FDA advisory committee meeting. For information pertaining to these products contact Xanodyne at 877-773-7793

August 5, 2008
Xanodyne Achieves Positive Efficacy Results in Pivotal Phase 3 Studies of Proprietary Modified Release Oral Tranexamic Acid Product Candidate for Heavy Menstrual Bleeding

July 22, 2008
Xanodyne Receives Approvable Letter From the U.S. Food and Drug Administration for ZIPSOR™ (diclofenac potassium) Capsules

February 6, 2008
Xanodyne Announces Two Senior Appointments